CytoGenix Announces Research Collaboration with Imperial College London for the Study of Antimicrobial Agent.HOUSTON -- CytoGenix Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYGX) announced that it has entered into a collaborative research agreement with Imperial College London History Imperial College was founded in 1907, with the merger of the City and Guilds College, the Royal School of Mines and the Royal College of Science (all of which had been founded between 1845 and 1878) with these entities continuing to exist as "constituent colleges". for research studies using the company's proprietary antimicrobial nucleic acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. compound. Professor Martin Buck of the Division of Biology at Imperial is the Principal Investigator Noun 1. principal investigator - the scientist in charge of an experiment or research project PI scientist - a person with advanced knowledge of one or more sciences for this research program to further elucidate the antimicrobial activity of CytoGenix RBL-1 compound. Dr. Buck's scientific interests include the understanding of the molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller of bacteria, particularly the specific function of bacterial RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic . Dr. Yin Chen, CytoGenix Vice President of Research and Chief Scientific Officer commented, "We are very pleased to collaborate with scientists of the caliber of Dr. Buck. The results of his work will further our understanding of this promising therapeutic compound." About Imperial College London Consistently rated in the top three UK university institutions, Imperial College London is a world-leading, science-based university whose reputation for excellence in teaching and research attracts students (11,000) and staff (6,000) of the highest international quality. Innovative research at the College explores the interface between science, medicine, engineering and management and delivers practical solutions that enhance the quality of life and the environment, underpinned by a dynamic enterprise culture. Website: www.imperial.ac.uk. About CytoGenix CytoGenix Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. : Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion